Bio Essence Corp
Datakwaliteit: 100%
BIOE
OTC
Manufacturing
Chemicals
€ 0,25
€ 0,00
(0,00%)
Marktkapitalisatie: 9,50 M
Prijs
€ 0,25
Marktkapitalisatie
9,50 M
Dagbereik
€ 0,20 — € 0,30
52-Weeksbereik
€ 0,05 — € 0,30
Volume
25.317
Openen € 0,20
50D / 200D Gem.
€ 0,08
201,93% above
50D / 200D Gem.
€ 0,08
206,00% above
Quick Summary
Belangrijkste Punten
Revenue grew 20,91% annually over 5 years — strong growth
Net margin of 47,23% shows strong profitability
Generating 1,57 M in free cash flow
P/E of 10,60 — trading at a low valuation
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 464,87%
Cash machine — converts 175,16% of earnings into free cash flow
Groei
Revenue Growth (5Y)
20,91%
Boven sectorgemiddelde (9,35%)
Revenue (1Y)485,78%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
N/A
ROICN/A
Net Margin47,23%
Op. Margin47,43%
Veiligheid
Debt / Equity
N/A
Current Ratio0,06
Interest Coverage411,72
Waardering
PE (TTM)
10,60
Boven sectorgemiddelde (-1,98)
P/B RatioN/A
EV/EBITDA10,59
Dividend YieldN/A
Koershistorie
Financiële Trends
Sectorvergelijking
vs Manufacturing sector mediaan (44 peers)
Sectorvergelijking
vs Manufacturing sector mediaan (44 peers)| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 10,6 | -2,0 |
| P/B | — | 5,1 |
| ROE % | — | -51,0 |
| Net Margin % | 47,2 | -150,2 |
| Rev Growth 5Y % | 20,9 | 9,3 |
| D/E | — | 0,3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 485,78% | Revenue Growth (3Y) | 85,49% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | 20,91% | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 1,90 M | Net Income (TTM) | 896.197,0 |
| ROE | N/A | ROA | 603,04% |
| Gross Margin | 75,28% | Operating Margin | 47,43% |
| Net Margin | 47,23% | Free Cash Flow (TTM) | 1,57 M |
| ROIC | N/A | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 0,06 |
| Interest Coverage | 411,72 | Asset Turnover | 12,77 |
| Working Capital | -3,05 M | Tangible Book Value | -3,10 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | 10,60 | Forward P/E | N/A |
| P/B Ratio | N/A | P/S Ratio | 5,01 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | 10,59 | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | 16,52% | ||
| Market Cap | 9,50 M | Enterprise Value | 9,53 M |
| Per Share | |||
| EPS (Diluted TTM) | N/A | Revenue / Share | 0,05 |
| FCF / Share | 0,04 | OCF / Share | 0,04 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 175,16% |
| SBC-Adj. FCF | N/A | Growth Momentum | 464,87 |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 1,90 M | 323.940,0 | 551.506,0 | 985.757,0 | 887.984,0 |
| Net Income | 896.197,0 | -1,31 M | -971.879,0 | -809.679,0 | -647.564,0 |
| EPS (Diluted) | — | -0,03 | -0,02 | -0,02 | — |
| Gross Profit | 1,43 M | 217.077,0 | 277.446,0 | 384.949,0 | 298.324,0 |
| Operating Income | 900.011,0 | -459.438,0 | -789.050,0 | -782.804,0 | -857.527,0 |
| EBITDA | — | — | — | — | — |
| R&D Expenses | — | — | — | — | — |
| SG&A Expenses | — | — | — | — | — |
| D&A | 235,0 | 911,0 | 17.418,0 | 53.977,0 | 35.802,0 |
| Interest Expense | 2.186,0 | 2.153,0 | 17.344,0 | — | 38.558,0 |
| Income Tax | 800,0 | 800,0 | 2.400,0 | 3.300,0 | 3.300,0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 422.474,0 | 281.024,0 | 2,66 M | 1,55 M | 1,70 M |
| Total Liabilities | 2,50 M | 3,25 M | 4,32 M | 4,79 M | 4,13 M |
| Shareholders' Equity | -2,07 M | -2,97 M | -1,66 M | -3,24 M | -2,43 M |
| Total Debt | 57.482,0 | 56.481,0 | — | — | — |
| Cash & Equivalents | — | 1.371,0 | 114,0 | 6.262,0 | 303,0 |
| Current Assets | 422.377,0 | 280.692,0 | 1,10 M | 203.831,0 | 261.962,0 |
| Current Liabilities | 2,44 M | 2,80 M | 3,18 M | 3,56 M | 2,76 M |
{"event":"ticker_viewed","properties":{"ticker":"BIOE","listing_kind":"stock","pathname":"/stocks/bioe","exchange":"OTC","country":"US"}}